OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
240
Results
Show all
Save search
Copy query
Show results for
Unknown
(232)
Clinical
(5)
Genomics
(2)
Proteomics
(1)
Organisms
Alphavirus
(1)
Anemia
(1)
Betaherpesvirinae
(1)
Borrelia
(1)
Cowpox virus
(1)
Coxsackievirus
(1)
Cytomegalovirus
(1)
Dengue virus
(1)
EFO:0001352
(1)
Filoviridae
(1)
Hepatitis B virus
(1)
Human alphaherpesvirus 1
(1)
Human betaherpesvirus 5
(1)
Human immunodeficiency virus
(1)
Human immunodeficiency virus 1
(1)
Human immunodeficiency virus 2
(1)
Influenza A virus
(1)
Influenza C virus
(1)
Japanese encephalitis virus group
(1)
Lyssavirus rabies
(1)
Middle East respiratory syndrome-related coronavirus
(1)
Nostoc sp. PCC 7120 = FACHB-418
(1)
Oropouche virus
(1)
Orthopoxvirus vaccinia
(1)
Rattus
(1)
Staphylococcus aureus
(1)
Streptococcus pneumoniae
(1)
Viruses
(1)
West Nile virus
(1)
cellular organisms
(1)
Organisms
Simian-Human immunodeficiency virus
(1)
Repository
ENA
(2)
pride
(1)
Tissue
Small intestine
(1)
Disease
Pancreatic Neoplasms
(3)
Neuroendocrine Tumors
(1)
Neoplasms
(1)
Small intestine cancer
(1)
Technology Type
Data-dependent acquisition
(1)
Mass Spectrometry
(1)
Publication Date
2026
(1)
First Public Date
2025
(1)
2017
(1)
Classification
viruses
(1)
Study status
Recruiting
(3)
Withdrawn
(1)
Not yet recruiting
(1)
Study type
Interventional
(5)
Release Date
2021
(44)
2023
(37)
2022
(35)
2025
(24)
2020
(23)
2024
(22)
2019
(13)
2018
(13)
2026
(7)
2017
(5)
2016
(4)
2015
(3)
2014
(2)
Lab affiliation
Department of Medical Radiation Sciences, University of Gothenburg, Sahlgrenska University Hospital, SE-413 45 Gothenburg, Sweden
(1)
Location
United States
(3)
Belgium
(2)
Netherlands
(2)
Poland
(1)
United Kingdom
(1)
South Korea
(1)
Spain
(1)
Italy
(1)
Canada
(1)
Brazil
(1)
France
(1)
Tags
xref:PubMed:27959928
(1)
pathogen:virus
(1)
pathogen
(1)
Keyword
Lutetium Lu 177 dotatate
(4)
PRRT
(2)
Copper
(1)
177Lu-DOTATATE
(1)
INTRON A
(1)
Peptide Receptor Radionuclide Therapy (PRRT)
(1)
Interferon alpha
(1)
Everolimus Accord 5mg Tablets
(1)
Szunitinib Mylan 12,5 mg
(1)
Octreotide LAR
(1)
SOMATULINE AUTOGEL 120 mg solution for injection in a pre-filled syringe
(1)
Sunitinib Mylan 12,5 mg
(1)
Szunitinib Sandoz 12,5 mg
(1)
RYZ101
(1)
Sandostatin® LAR®- Monatsdepot 30 mg powder and solvent for suspension for injection
(1)
SSTR+
(1)
Targeted radiotherapy
(1)
RayzeBio
(1)
Actinium
(1)
Ac 225
(1)
Dotatate
(1)
Alpha emitter
(1)
Octreotide
(1)
LysaKare 25g / 25g solution for infusion
(1)
NETs
(1)
Carcinoid tumors
(1)
LysaKare
(1)
Arginine/lysine
(1)
Amino acid
(1)
Peptide Receptor Radionuclide Therapy
(1)
Previous
page
1 / 24
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
24
Next
page
Sort
by:
Relevance
Page size
10
Combination Therapies with PRRT.
Not available
S-EPMC8538931
|
biostudies-literature
Cite
PRRT plus holmium-166-SIRT (HEPAR PLuS) versus PRRT-only in patients with metastatic neuroendocrine tumors: A propensity-score matched analysis.
Not available
S-EPMC12358199
|
biostudies-literature
Cite
New Insights in PRRT: Lessons From 2021.
Not available
S-EPMC9016202
|
biostudies-literature
Cite
Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate.
Not available
S-EPMC4969358
|
biostudies-literature
Cite
Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT.
Not available
S-EPMC8395467
|
biostudies-literature
Cite
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.
Not available
S-EPMC7515632
|
biostudies-literature
Cite
Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements.
Not available
S-EPMC10251822
|
biostudies-literature
Cite
PReCedeNT trial: Phase III randomized-controlled trial of Lutetium - 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Not available
S-EPMC12560366
|
biostudies-literature
Cite
Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT.
Not available
S-EPMC8484673
|
biostudies-literature
Cite
Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).
Not available
S-EPMC10750196
|
biostudies-literature
Cite
Previous
page
1 / 24
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
24
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
